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Abstract -Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive human malignancy. It is known that distur-
bances in apoptotic pathways have a great impact on tumor progression and aggressiveness. In this study the apoptosis-
related molecules Bcl-2 (antiapoptotic), Bax (proapoptotic) and survivin (an inhibitor of apoptosis) were analyzed im-
munohistochemically in thirty archival cases of ATC. In situ apoptotic cell death was analyzed by the TUNEL method. 
Mean Bcl-2 staining score (calculated from individual scores from 0-3) was low compared to those for Bax and survivin 
(p<0.05). High expression of survivin was associated with high Bax expression, and was significantly segregated from high 
Bcl-2 expressing cases (p<0.05). Despite high Bax expression, apoptotic cell death was low in the investigated carcinomas. 
In addition, the mean apoptotic index in high survivin expressing carcinomas was significantly lower than in low survivin 
expressing carcinomas (p<0.05). It could be concluded that down-regulation of Bcl-2 is counterbalanced by up-regulation 
of survivin, which may overcome the effects of high Bax expression, and, at least partly, explain the low apoptosis rate and 
high biological aggressiveness of ATC.
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INTRODUCTION
Malignant tumors of the thyroid gland are classi-
fied as papillary, follicular, medullary and anaplastic. 
Carcinomas originating from the follicular epithe-
lium  are  generally  divided  into  two  groups:  well-
differentiated  (papillary  or  follicular)  carcinomas 
and undifferentiated (anaplastic) carcinoma, while 
medullary carcinoma originates from parafollicular 
thyroid cells.
Contrary  to  well-differentiated  carcinomas, 
which in general have a favorable prognosis, ana-
plastic thyroid carcinoma (ATC) is one of the most 
malignant and aggressive types of human tumors. 
The  majority  of  patients  diagnosed  with  ATC  die 
within a few months after diagnosis due to suffoca-
tion as a consequence of locoregional disease exten-
sion or overwhelming distant metastases (Aldinger 
et al., 1978; Giuffrida et al., 2000; O’ Neill et al., 2005; 
Wiseman et al., 2007).
Great clinical efforts have been made to control 
the disease locally, since it is usually very aggressive 
and invasive when diagnosed. In addition, molecu-
lar and genetic changes underlying the progression 956 SONJA ŠELEMETJEV  ET AL.
of malignancy of thyroid tumors have been the sub-
ject of numerous investigations (Smallridge et al., 
2009).
It is well-established that two processes, pro-
liferation and apoptosis (programmed cell death), 
have  a  great  impact  on  tumor  progression  and 
aggressiveness.  Apoptosis  is  a  form  of  physi-
ological cell death driven by an intrinsic cellular 
suicide  program  aimed  at  excluding  unwanted, 
infected or transformed cells without inflamma-
tion. The mechanism involved in the regulation 
of  cell  death  is  not  yet  completely  understood, 
but members of the Bcl-2 family of proteins and 
their activators and inhibitors, seem to be the key 
regulators of this process (Burlacu, 2003; Kirkin 
et  al.,  2004).  Bcl-2  protein  is  an  antiapoptotic 
molecule that maintains the integrity of the mi-
tochondrial membrane by preventing cytochrome 
c release from the mitochondria, which is needed 
for the proteolytic degradation of the cell by cas-
pases  (proteolytic  enzymes)  which  are  the  final 
executors of programmed cell death. Unlike Bcl-
2, its homologue Bax, a cytosolic protein, allows 
disruption of the mitochondrial membranes and 
caspases activation. The Bax gene (transcription-
ally activated by p53, a tumor suppressor protein), 
was established as an inhibitory regulator of cell 
proliferation (Levine et al., 1991). If unsuccessful, 
p53 can also eliminate cells through the Bcl-2/Bax 
apoptotic pathway. The ratio between Bcl-2 and 
Bax appears to be important in deciding cell life or 
death (Reed, 1994).
Abnormalities in the control of programmed cell 
death play an important role in tumorigenesis. The 
expression of apoptosis-related molecules in thyroid 
carcinoma  has  been  widely  investigated,  although 
with  some  controversial  reports.  The  low  rate  of 
apoptotic cell death in thyroid carcinomas, and es-
pecially in ATC, despite the presence of the proap-
optotic molecule Bax and tumor suppressor-p53, is 
still not understood (Manetto et al., 1997; Moore et 
al., 1998; Yoshida et al., 1999; Sreelekha et al., 2000; 
Farid et al., 2001; Saltman et al., 2006; Cvejic et al., 
2009).
A candidate molecule influencing the apoptotic 
balance in cancer was identified as survivin (Ambro-
sini et al., 1997), a member of the inhibitor of the 
apoptosis protein (IAP) family (Deveraux and Reed, 
1999).  Survivin  is  a  multifunctional  protein  that 
suppresses  apoptosis  by  inhibiting  caspase-3  and 
-7 activities (Tamm et al., 1998) and regulates the 
cell cycle in the G2/M phase (Li et al., 1998; Altieri, 
2001). Unique among other IAP proteins, survivin is 
expressed during embryonic and fetal development. 
It is undetectable in normal adult tissues, but it is 
prominently overexpressed in the most common hu-
man cancers, including breast, gastric and colorectal 
carcinomas and lymphomas (Ambrosini et al., 1997; 
Duffy et al., 2007).
Thus, to gain a better insight into the molecular 
disturbances which underlie the biological behavior 
of ATC, we examined the expression of the apoptosis 
related molecules: Bcl-2 (antiapoptotic), Bax (proap-
optotic), survivin (apoptosis inhibitory protein) and 
furthermore analyzed in situ apoptotic cell death in 
these tumors.
MATERIAL AND METHODS
Tissue samples
Thirty formalin-fixed, paraffin-embedded tissues 
of  anaplastic  thyroid  carcinoma  were  obtained 
from the archival material of the Institute of Endo-
crinology, Diabetes and Diseases of Metabolism, 
KCS, Belgrade. Histological slides from the thy-
roid tumor tissue stained with hematoxylin and 
eosin were reevaluated by the pathologist. Cyto-
logical features (large polygonal or spindle-shaped 
cells,  frequently  multinucleated  and  containing 
abnormal mitotic figures) confirmed the diagno-
sis of ATC.
Immunohistochemistry
Immunohistochemistry  was  performed  using 
monoclonal antibodies against human Bcl-2 (clone 
Bcl  2-100,  Sigma,  Germany)  and  survivin  (clone 
SPM331, Abcam plc, Cambridge, UK), and rabbit SURVIVIN IN ANAPLASTIC ThyROID CARCINOMA 957
polyclonal antibody against Bax (Dako, Carpinteria, 
California, USA). Positive reactions were identified 
using  a  streptavidin-biotin-peroxidase  detection 
system  (Vector  Laboratories,  Burlingame,  Cali-
fornia, USA). Tissue sections (4-6 µm thick) from 
each block were deparaffinized with xylene and re-
hydrated through a series of descending concentra-
tions  of  ethanol.  Endogenous  peroxidase  activity 
was blocked with 0.3% H2O2/methanol for 30 min 
followed  by  incubation  with  non-immune  horse 
serum for 20 min to block non-specific binding. 
Tissue sections were then incubated with primary 
antibody  against  Bcl-2  (1:200  dilution),  primary 
antibody  against  Bax  (1:25  dilution)  or  primary 
antibody against survivin (1:250) at 4˚C overnight. 
This was followed by incubation with biotinylated 
horse anti-mouse IgG (for Bcl-2 and survivin) or 
with biotinylated goat-anti rabbit IgG (for Bax) for 
30 min and thereafter with the avidin-biotin-perox-
idase complex for 30 min. Between each step, sec-
tions were washed three times in phosphate buff-
ered saline (PBS). The reaction was visualized using 
3, 3’-diaminobenzidine tetra hydrochloride (DAB) 
solution as a chromogen. After counterstaining with 
hematoxylin the slides were dehydrated in ascend-
ing ethanol, cleared with xylene, mounted with cov-
erslips using a permanent mounting medium and 
thereafter examined using a Reichert-Jung micro-
scope supplied with a Photostar automatic camera 
system. Controls were incubated with PBS in place 
of the primary antibody and no positive staining 
was observed.
Scoring of immunohistochemical staining
Cytoplasmic staining for Bcl-2, Bax and survivin was 
scored by two independent observers as follows: (-, 
0) no staining; (-/+, 1) weak or focal staining; (+, 2) 
moderate staining in the majority of cells and (++, 
3) strong staining in the majority of cells. The mean 
staining  scores  for  Bcl-2,  Bax  and  survivin  were 
calculated (mean ± SD) from the individual stain-
ing score for each case (0-3) in the group. For ease 
of comparison, Bcl-2, Bax and survivin expressions 
were dichotomized into low expression (0-1) versus 
high expression (2-3).
In situ detection of apoptotic cells
Apoptotic cells in the tissue sections were detected 
by the terminal deoxynucleotidyl transferase-medi-
ated  deoxyuridine  triphosphate  nick-end  labeling 
technique  (TUNEL),  using  a  commercial  apopto-
sis kit (TACS TM TdT Kit, R&D Systems Inc., Min-
neapolis, USA), according to the supplier’s instruc-
tions. In brief, the tissue sections of 30 cases of ATC 
were  deparaffinized  with  xylene  and  ethanol  and 
rinsed with PBS. The sections were then treated with 
proteinase K in PBS, followed by quenching of en-
dogenous  peroxidase.  Biotinylated  dNTP  mix  was 
added to the 3’-OH ends of DNA by terminal de-
oxynucleotidyl  transferase  (TdT).  After  incubating 
with  streptavidin-horseradish  peroxidase,  the  sec-
tions  were  stained  with  diaminobenzidine  (DAB) 
and  counterstained  with  hematoxylin.  Finally,  the 
sections  were  dehydrated  in  ethanol,  cleared  with 
xylene and mounted with coverslips in a permanent 
medium. Experimental controls included during the 
performance of the TUNEL method protocol were: 
TACS-nuclease-treated thyroid tissue sections as a 
positive control and the omission of the TdT reaction 
step as a negative control, according to the supplier’s 
instructions.
The percentage of apoptotic cells was determined 
by light microscope examination. The mean apoptot-
ic score was calculated (mean ± SD) from the indi-
vidual staining scores for each case in the group, and 
assigned as an Apoptotic Index (AI).
Ethical issues
The study protocol was approved by the Ethics Com-
mittee  at  the  Clinical  Center  of  Serbia,  Belgrade, 
which conforms to the provisions of the Declaration 
of Helsinki.
Statistical analysis
Statistical comparisons of data were made using χ2 
test, Fisher’s exact test or the Mann-Whitney U-test, 
as indicated in the Results section. A value p<0.05 
was considered to be statistically significant.958 SONJA ŠELEMETJEV  ET AL.
RESULTS
Our immunohistochemical staining results are pre-
sented in Tables 1-3 and representative microphoto-
graphs are shown in Fig. 1 (A-D).
Immunohistochemical expression of Bcl-2 pro-
tein  was  visualized  as  cytoplasmic  staining  and 
found in 24 of the 30 ATC cases analyzed, but mostly 
as weak or focal staining (Table 1, Fig. 1-A). There 
were only 8 cases (26.6%) which exhibited moderate 
expression of Bcl-2 (scores 2), which indicates scarci-
ty of this antiapoptotic protein in anaplastic thyroid 
cancer cells.
Bax protein was expressed in 29 of the 30 cases 
of ATC (Fig. 1-B), with strong staining intensity in 
most of them, i.e. 24 (80.0%) cases were in the high 
Bax expressing group (scores 2 or 3).
Immunohistochemical staining for survivin re-
vealed cytoplasmic positivity of cancer cells in 27 
of the 30 cases (90.0%). Occasionally, some nuclei 
were also found to be positive. The distribution of 
Fig.1. Immunohistochemical expression of Bcl-2, Bax and survivin and in situ detection of apoptotic cells in anaplastic thyroid carcino-
ma. (A) Low cytoplasmic positivity for Bcl-2. (B) High Bax cytoplasmic immunopositivity. (C) High immunohistochemical expression 
of survivin. (D) In situ labeling for apoptosis in the corresponding area of (C) detected only one apoptotic tumor cell (arrow).
ABC technique, hematoxylin diaminobenzidine: A, B, C. TUNEL technique, hematoxylin diaminobenzidine: D. Original magnifica-
tions: A x20; B,C,D x40.SURVIVIN IN ANAPLASTIC ThyROID CARCINOMA 959
Table 1. Immunohistochemical expression of Bcl-2, Bax and survivin in anaplastic thyroid carcinoma (ATC).
Staining score Bcl-2 Bax survivin
  - (0) 6 1 3
-/+ (1) 16 5 6
 + (2) 8 10 4
++ (3) 0 14 17
Mean score 1.067 ± 0.691a 2.233 ± 0.858b 2.462 ± 1.085c
Staining score: (-,0) no staining; (-/+,1) weak or focal staining; (+,2) moderate staining in the majority of cells, (++,3) strong staining 
in the majority of cells.
Mean score: as detailed in Material and Methods section.
Statistically significant differences (p<0.05) for a versus b and a versus c (Mann-Whitney U-test). 
Table 2. Correlation between immunohistochemical expression of survivin and Bcl-2 or Bax expression in anaplastic thyroid carcinoma 
(ATC).
Survivin high expressing cases (n=21)
Bcl-2 low expressing cases 16/21 (76.2 %)
Bcl-2 high expressing cases  5/21 (23.8 %)a
 Bax low expressing cases 4/21 (19.1 %)
 Bax high expressing cases 17/21 (81.0 %)b
Low expressing cases: staining scores (-,0) and (-/+,1). High expressing cases: staining scores (+,2) and (++,3).
Statistically significant difference (p<0.05) for a versus b (Fisher’s exact test).
Table 3. The relationship between survivin expression and apoptotic cell death in anaplastic thyroid carcinoma (ATC).
n AI (%)
Survivin low expressing cases 9 0.556 ± 0.527a
Survivin high expressing cases 21 0.143 ± 0.359b
AI: as detailed in Material and Methods section.
Statistically significant difference (p<0.05) for a versus b (Mann-Whitney U-test).960 SONJA ŠELEMETJEV  ET AL.
survivin immunohistochemical scores showed that 
21 (70.0%) cases were in the high expressing group 
(Table 1, Fig. 1-C).
Since positive carcinomas showed variability in 
the  immunostaining  pattern  of  the  analyzed  pro-
teins, the average staining scores for Bcl-2, Bax and 
survivin were calculated (mean ± SD) from the indi-
vidual staining scores for each case (0-3). Thus, the 
average staining score for Bax and survivin (2.233 ± 
0.858 and 2.462 ± 1.085, respectively) showed that 
these proteins were expressed at similar high levels 
in  ATC,  while  the  average  staining  score  for  Bcl-
2 (1.067 ± 0.691) was significantly lower (p<0.05; 
Mann-Whitney U-test). 
The relationship between survivin and Bcl-2 or 
Bax is presented in Table 2. High expression of sur-
vivin showed a strong positive correlation with the 
high expression of Bax, and it was significantly segre-
gated from high Bcl-2-expressing cases (17/21, 81.0 
% versus 5/21, 23.8 %; p<0.05; Fisher’s exact test). 
The number of apoptotic cells detected by in situ 
labeling was low, with zero up to ten positive cells 
per 10 HPFs in most of the carcinomas studied. The 
mean AI of the 30 ATC cases analyzed was 0.267 % 
(SD,  0.449%).  The  relationship  between  apoptotic 
cell death and survivin expression was examined and 
is presented in Table 3 and Fig. 1-C, D. The mean AI 
in high survivin expressing carcinomas was 0.143% 
(DS, 0.359%), which was significantly lower than the 
mean AI of 0.556% (SD, 0.527%) observed in low 
survivin expressing tumors (p<0.05; Mann-Whitney 
U-test).
DISCUSSION
Anaplastic thyroid carcinoma (ATC) is a rare and 
rapidly lethal human malignancy. The biological be-
havior of each tumor depends on a number of fac-
tors, including the balance between proliferation and 
programmed cell death (apoptosis). As a fast growing 
tumor, anaplastic thyroid carcinoma is characterized 
by a high proliferative capacity that is not counterbal-
anced by an appropriate rate of apoptotic cell death. 
Although the expression of the genes regulating ap-
optosis in thyroid malignant tissue has been exten-
sively studied during the last years, the complexity of 
genetic defects in the apoptotic pathways in thyroid 
carcinomas are still not clearly understood. In this 
study we examined the expression of apoptosis-re-
lated molecules: Bcl-2 (antiapoptotic), Bax (proap-
optotic), survivin (apoptosis inhibitory protein) and 
furthermore analyzed in situ apoptotic cell death in 
anaplastic thyroid carcinoma.
The Bcl family of proteins plays an important role 
in the regulation of apoptosis (Burlacu, 2003; Kirkin 
et al., 2004). Representative members of this family 
are Bcl-2 and Bax. With regards to thyroid tumors, 
there is general agreement that Bcl-2 is expressed at 
high levels in normal thyroid tissue as well as in well- 
differentiated thyroid carcinomas (Pilotti et al., 1994; 
Pollina et al., 1996; Moore et al.,1998; Mitselou et al., 
2004; Aksoy et al., 2005; Cvejic et al., 2008). How-
ever, its expression was reported to decrease with 
dedifferentiation and aggressiveness (Pollina et al., 
1996; Moore et al., 1998; Saltman et al., 2006; Cvejic 
et al., 2009). In this study we found low expression of 
Bcl-2 protein in the ATC cases analyzed, which is in 
agreement with previous reports.
The proapoptotic molecule Bax has been inves-
tigated to a lesser extent in thyroid carcinomas, with 
conflicting results, and its role in thyroid tumorigen-
esis and tumor biology is controversial. While some 
authors could not detect Bax in differentiated thyroid 
carcinomas (Manetto et al., 1997), others reported 
Bax expression in all or in the majority of differenti-
ated carcinomas investigated (Hermann et al., 2001; 
Letsas et al., 2005). Considering Bax expression in 
ATC, Branet et al. (1996) reported that it was either 
not expressed or was only weakly expressed, while 
Manetto et al. (1997) found strong staining for Bax in 
ATC. The results of our previous (Cvejic et al., 2009) 
and current study revealed high cytoplasmic expres-
sion of Bax in almost all cases of ATC. 
Considering the high Bax and low Bcl-2 expres-
sion levels demonstrated in ATC, and the fact that 
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between proapoptotic and antiapoptotic factors, it 
should be expected that this type of thyroid cancer 
exhibits an increased apoptotic death rate (Yoshida 
et al., 1999; Sreelekha et al., 2000). However, we have 
observed here that, in spite of high Bax and low Bcl-2 
expression, there was a low apoptotic index in ATC. 
With regard to the complexity of the proapoptotic 
and  antiapoptotic  pathways,  with  multiple  factors 
involved, down-regulation of only one antiapoptotic 
factor (i.e. Bcl-2) may not always result in enhance-
ment  of  apoptotic  cell  death.  Thus,  other  defects 
across the apoptotic pathway in the malignant cell, 
for example defects in the functions of downstream 
effectors of Bax, such as caspases, with their activa-
tors and inhibitors, should be considered.
In this study we investigated survivin expression 
in ATC for the first time along with analysis of Bcl-2 
and Bax expression, and analyzed their relation to in 
situ apoptotic cell death.
Survivin is a recently identified inhibitor of ap-
optosis (IAP), which directly inhibits caspase-3 and-
7 activities and regulates the cell cycle in the G2/M 
phase,  being  therefore  a  bifunctional  protein  that 
acts as a suppressor of apoptosis and plays a role in 
cell proliferation (Tamm et al., 1998; Li et al., 1998). 
Survivin has been found to be strongly expressed in 
many common human cancers (Duffy et al., 2007) 
and in some of them, for example in breast cancer, 
overexpression of this protein has been considered to 
be a poor prognostic factor (Tanaka et al., 2000).
There are only a few studies on survivin expres-
sion in thyroid carcinomas. Survivin protein was de-
tected in well-differentiated thyroid carcinomas by 
Haghpanah et al. (2006), Antonaci et al. (2008) and 
Dong et al. (2006), but there are only few data on sur-
vivin immunohistochemical expression in ATC. Ito 
et al. (2003) found a higher incidence of survivin ex-
pression in ATC (84 %) than in papillary carcinoma 
(20 %) cases, suggesting that this protein is related to 
the dedifferentiation of thyroid carcinoma. Similarly, 
Zhang et al. (2009) reported that overexpression of 
survivin in ATC compared with well- differentiated 
carcinoma is an unfavorable prognostic factor.
Our results revealed survivin immunohistochem-
ical expression in 90.0 % of the ATC cases examined. 
In addition, high expression of survivin showed a 
strong positive correlation with high Bax expression 
and reduced apoptosis rate. Thus, a characteristic of 
ATC is the high expression of survivin, accompanied 
by a high expression of Bax, low expression of Bcl-2 
and low apoptotic cell death.
The existence of a low apoptosis and elevated 
survivin expression suggests an apoptosis inhibi-
tory  function  for  survivin  in  anaplastic  thyroid 
carcinoma. While Bcl-2, as an antiapoptotic mole-
cule, exerts its effect by maintaining mitochondrial 
membrane integrity and thereby prevents the ap-
optotic effects of Bax (Burlacu, 2003; Kirkin et al., 
2004), survivin exerts its antiapoptotic function in 
Bax downstream pathways by targeting caspase-3 
(Tamm et al., 1998). Thus, it seems that down-reg-
ulation of Bcl-2 is counterbalanced with an up-reg-
ulation of survivin, which may overcome the effects 
of high Bax expression, and, at least partly, explain 
the low apoptosis rate and high biological aggres-
siveness of ATC. In this context, survivin-targeted 
therapy might be promising for these patients in the 
future.
Acknowledgment -  Supported by the Ministry of Education 
and Science of the Republic of Serbia, project 173050; “Mo-
lecular characterization of thyroid gland tumors: biological 
and clinical aspects.”
REFERENCES
Aksoy, M., Giles, Y., Kapran, Y., Terzioglu, T., and S. Tezelman 
(2005). Expression of Bcl-2 in papillary thyroid cancers 
and its prognostic value. Acta Chir. Belg. 105, 644-648.
Aldinger, K.A., Samaan, N.A., Ibanez, M., and C.S.Jr. Hill (1978). 
Anaplastic carcinoma of the thyroid: a review of 84 cases 
of spindle and giant cell carcinoma of the thyroid. Cancer, 
41, 2267-2275.
Altieri, D.C. (2001). The molecular basis and potential role of 
survivin  in  cancer  diagnosis  and  therapy.  Trends  Mol. 
Med. 7, 542-547.
Ambrosini, G., Adida, C., and D.C. Altieri (1997). A novel anti-
apoptosis gene, survivin, expressed in cancer and lympho-
ma. Nat. Med. 3, 917-921.962 SONJA ŠELEMETJEV  ET AL.
Antonaci, A., Consorti, F., Mardente, S., Natalizi, S., Giovannone, 
G., and C. Della Rocca (2008). Survivin and cyclin D1 are 
jointly expressed in thyroid papillary carcinoma and mi-
crocarcinoma. Oncol. Rep. 20, 63-67.
Branet, F., Brousset, P., Krajewski, S., Schlaifer, D., Selves, J., Reed, 
J.C., and P. Caron (1996). Expression of the cell death-in-
ducing gene Bax in carcinomas developed from the folli-
cular cells of the thyroid gland. J. Clin. Endocrinol. Metab. 
81, 2726-2730.
Burlacu, A.(2003). Regulation of apoptosis by Bcl-2 family pro-
teins. J. Cell. Mol. Med. 7, 249-257.
Cvejic, D., Selemetjev, S., Savin, S., Paunovic, I., Petrovic, I., and 
S. Tatic (2008). Apoptosis and proliferation related mol-
ecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcino-
ma versus papillary carcinoma of the thyroid. Pathology, 
40, 475-480.
Cvejic,  D.,  Selemetjev,  S.,  Savin,  S.,  Paunovic,  I.,  and  S.  Tatic 
(2009). Changes in the balance between proliferation and 
apoptosis during the progression of malignancy in thyroid 
tumours. Eur. J. Histochem. 53, 65-72.
Deveraux, Q.L., and J.C. Reed (1999). IAP family proteins – sup-
pressors of apoptosis. Genes Dev. 13, 239-252.
Dong, W., Li, X., Lu, X., Di, B., Ma, J., and L. Cui (2006). Expres-
sion of survivin and its correlation with tumor angiogen-
esis in differentiated thyroid carcinomas. Lin Chuang Er Bi 
Yan Hou Ke Za Zhi, 20, 967-969. (Chinese)
Duffy, M.J., O’Donovan, N., Brennan, D.J., Gallagher, W.M., and 
B.M Ryan (2007). Survivin: a promising tumor biomarker. 
Cancer Lett. 249, 49-60.
Farid, P., Gomb, S.Z., Peter, I., and B. Szende (2001). Bcl-2, p53 
and bax in thyroid tumors and their relation to apoptosis. 
Neoplasma, 48, 299-301.
Giuffrida, D., and H. Gharib (2000). Anaplastic thyroid carci-
noma: current diagnosis and treatment. Ann. Oncol. 11, 
1083-1089.
Haghpanah, V., Shooshtarizadeh, P., Heshmat, R., Larijani, B., 
and S.M. Tavangar (2006). Immunohistochemical analysis 
of survivin expression in thyroid follicular adenoma and 
carcinoma.  Appl.  Immunohistochem.  Mol.  Morphol.  14, 
422-425.
Hermann, S., Sturm, I., Mrozek, A., Klosterhalfen, B., Hauptmann, 
S., Dörken, B., and P.T. Daniel (2001). Bax expression in 
benign and malignant thyroid tumours: dysregulation of 
wild type P53 is associated with a high Bax and P21 ex-
pression in thyroid carcinoma. Int. J. Cancer, 92, 805-811.
Ito, Y., Yoshida, H., Uruno, T., Nakano, K., Miya, A., Kobayashi, 
K., Yokozawa, T., Matsuzuka, F., Matsuura, N., Kakudo, K., 
Kuma, K., and A. Miyauchi (2003). Survivin expression is 
significantly linked to the dedifferentiation of thyroid car-
cinoma. Oncol. Rep. 10, 1337-1340.
Kirkin, V., Joos, S., and M. Zörnig (2004) . The role of Bcl-2 family 
members in tumorigenesis. Biochim. Biophys. Acta, 1644, 
229-249.
Letsas, K.P., Frongou-Lazaridis, M., Skyrlas, A., Tsatsoulis, A., 
and V. Malamou-Mitsi (2005). Transcription factor-medi-
ated proliferation and apoptosis in benign and malignant 
thyroid lesions. Pathol. Int. 55, 694-702.
Levine, A.J., Momand, J., and C.A. Finlay (1991). The p53 tumor 
suppressor gene. Nature, 351, 453-456.
Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, 
P.C.,  and D.C.  Altieri  (1998).  Control  of  apoptosis  and 
mitotic spindle checkpoint by survivin. Nature, 396, 580-
584.
Manetto, V., Lorenzini, R., Cordon-Cardo, C., Krajewski, S., Rosai, 
J., Reed, J.C., and V. Eusebi (1997). Bcl-2 and Bax expres-
sion in thyroid tumours. An immunohistochemical and 
western blot analysis. Virchow Arch. 430, 125-130.
Mitselou, A., Peschos, D., Dallas, P., Charalabopoulos, K., Agnan-
tis, N.J., and T.Vougiouklakis (2004). Immunohistochemi-
cal  analysis  of  expression  of  bcl-2  protein  in  papillary 
carcinomas and papillary microcarcinomas of the thyroid 
gland. Exp. Oncol. 26, 282-286.
Moore,  D.,  Ohene-Fianko,  D.,  Garcia,  B.,  and  S.  Chakrabarti 
(1998). Apoptosis in thyroid neoplasms: relationship with 
p53 and Bcl-2 expression. Histopathology, 32, 35-42.
O’ Neill, J.P., O’ Neill, B., Condron, C., Walsh, M., and D. Bouch-
ier-Hayes  (2005).  Anaplastic  (undifferentiated)  thyroid 
cancer: improved insight and therapeutic strategy into a 
highly aggressive disease. J. Laryngol. Otol. 119, 585-591.
Pilotti, S., Collini, P., Rilke, F., Cattoretti, G., Del Bo, R., and M.A. 
Pierotti  (1994).  Bcl-2  protein  expression  in  carcinomas 
originating from the follicular epithelium of the thyroid 
gland. J. Pathol. 172, 337-342.
Pollina, L., Pacini, F., Fontanini, G., Vignati, S., Bevilacqua, G., and 
F. Basolo (1996). Bcl-2, p53 and proliferating cell nuclear 
antigen expression are related to the degree of differentia-
tion in thyroid carcinomas. Br. J. Cancer, 73,139-143.
Reed, J.C (1994). Bcl-2 and the regulation of programmed cell 
death. J. Cell Biol. 124, 1-6.
Saltman, B., Singh, B., Hedvat, C.V., Wreesmann, V.B., and R. 
Ghossein (2006). Patterns of expression of cycle/apoptosis 
genes along the spectrum of thyroid carcinoma progres-
sion. Surgery, 140, 899-905.
Smallridge, R.C., Marlow, L.A., and J.A. Copland (2009). Anaplas-
tic thyroid cancer: molecular pathogenesis and emerging 
therapies. Endocr. Relat. Cancer, 16, 17-44.SURVIVIN IN ANAPLASTIC ThyROID CARCINOMA 963
Sreelekha, T.T., Pradeep, V.M., Vijayalakshmi, K., Belthazar, A., 
Chellam, V.G., Nair, M.B., and M.P. Pillai (2000). In situ 
apoptosis in the thyroid. Thyroid, 10, 117-122.
Tamm, I., Wang, Y., Sausville, E., Scudiero, D.A., Vigna, N., Olt-
ersdorf, T., and J.C. Reed (1998). IAP-family protein sur-
vivin inhibits caspase activity and apoptosis induced by 
Fas (CD95), Bax, caspase and anticancer drugs. Cancer 
Res. 58, 5315-20.
Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., and 
N. Tanigawa (2000). Expression of survivin and its rela-
tionship to loss of apoptosis in breast carcinomas. Clin. 
Cancer Res. 6, 127-134.
Wiseman, S.M., Masoudi, H., Niblock, P., Turbin, D., Rajput, A., 
Hay, J., Bugis, S., Filipenko, D., Huntsman, D., and B. Gilks 
(2007). Anaplastic thyroid carcinoma: Expression profile 
of targets for therapy offers new insights for disease treat-
ment. Ann Surg. Oncol. 14, 719-729.
Yoshida, A., Nakamura, Y., Imada, T., Asaga, T., Shimizu, A., and 
M. Harada (1999). Apoptosis and proliferative activity in 
thyroid tumors. Surg. Today, 29, 204-208.
Zhang, H.Y., Meng, X., Du, Z.X., Fang, C.Q., Liu, G.L., Wang, 
H.Q., and W.W. Deng (2009). Significance of survivin, cas-
pase-3 and VEGF expression in thyroid carcinoma. Clin. 
Exp. Med. 9, 207-213.